These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1158 related articles for article (PubMed ID: 29018938)

  • 1. Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG).
    Tschöpe C; Birner C; Böhm M; Bruder O; Frantz S; Luchner A; Maier L; Störk S; Kherad B; Laufs U
    Clin Res Cardiol; 2018 Jan; 107(1):1-19. PubMed ID: 29018938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball.
    Tschöpe C; Van Linthout S; Kherad B
    Curr Cardiol Rep; 2017 Aug; 19(8):70. PubMed ID: 28656481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Heart Failure with Preserved Ejection Fraction.
    Ilieșiu AM; Hodorogea AS
    Adv Exp Med Biol; 2018; 1067():67-87. PubMed ID: 29498023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
    Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Rickenbacher P; Kaufmann BA; Maeder MT; Bernheim A; Goetschalckx K; Pfister O; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2017 Dec; 19(12):1586-1596. PubMed ID: 28295985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.
    Beldhuis IE; Streng KW; Ter Maaten JM; Voors AA; van der Meer P; Rossignol P; McMurray JJ; Damman K
    Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28209765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure with preserved ejection fraction: controversies, challenges and future directions.
    Zakeri R; Cowie MR
    Heart; 2018 Mar; 104(5):377-384. PubMed ID: 29305560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target.
    Manolis AS; Manolis AA; Manolis TA; Melita H
    Heart Fail Rev; 2019 Nov; 24(6):847-866. PubMed ID: 31147814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.
    Farmakis D; Simitsis P; Bistola V; Triposkiadis F; Ikonomidis I; Katsanos S; Bakosis G; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
    Clin Res Cardiol; 2017 May; 106(5):359-368. PubMed ID: 27999929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.
    Polsinelli VB; Shah SJ
    Expert Opin Pharmacother; 2017 Mar; 18(4):399-409. PubMed ID: 28129699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting heart failure with preserved ejection fraction: current status and future prospects.
    Kanwar M; Walter C; Clarke M; Patarroyo-Aponte M
    Vasc Health Risk Manag; 2016; 12():129-41. PubMed ID: 27143907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence.
    Del Buono MG; Iannaccone G; Scacciavillani R; Carbone S; Camilli M; Niccoli G; Borlaug BA; Lavie CJ; Arena R; Crea F; Abbate A
    Prog Cardiovasc Dis; 2020; 63(5):570-584. PubMed ID: 32387101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study.
    Özlek B; Özlek E; Ağuş HZ; Tekinalp M; Kahraman S; Çil C; Çelik O; Başaran Ö; Doğan V; Kaya BC; Rencüzoğulları I; Ösken A; Bekar L; Çakır MO; Çelik Y; Mert KU; Sancar KM; Sevinç S; Mert GÖ; Biteker M
    Eur J Intern Med; 2019 Mar; 61():88-95. PubMed ID: 30446354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular ejection fraction as therapeutic target: is it the ideal marker?
    Katsi V; Georgiopoulos G; Laina A; Koutli E; Parissis J; Tsioufis C; Nihoyannopoulos P; Tousoulis D
    Heart Fail Rev; 2017 Nov; 22(6):641-655. PubMed ID: 28601914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Inorganic Nitrate Versus Placebo Treatment in Heart Failure with Preserved Ejection Fraction.
    Gui Y; Chen J; Hu J; Ouyang M; Deng L; Liu L; Sun K; Tang Y; Xiang Q; Xu J; Zhu L; Peng Z; Zou P; Li B; Zheng Z; Xu D
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):503-513. PubMed ID: 32394177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical Therapy for Heart Failure Caused by Ischemic Heart Disease.
    Elgendy IY; Mahtta D; Pepine CJ
    Circ Res; 2019 May; 124(11):1520-1535. PubMed ID: 31120824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical therapy in heart failure with preserved ejection fraction: A systematic review.
    Palau P; Núñez E; Domínguez E; Sanchis J; Núñez J
    Eur J Prev Cardiol; 2016 Jan; 23(1):4-13. PubMed ID: 25488549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial.
    Feldman T; Mauri L; Kahwash R; Litwin S; Ricciardi MJ; van der Harst P; Penicka M; Fail PS; Kaye DM; Petrie MC; Basuray A; Hummel SL; Forde-McLean R; Nielsen CD; Lilly S; Massaro JM; Burkhoff D; Shah SJ;
    Circulation; 2018 Jan; 137(4):364-375. PubMed ID: 29142012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart Failure with Preserved Ejection Fraction.
    Gladden JD; Chaanine AH; Redfield MM
    Annu Rev Med; 2018 Jan; 69():65-79. PubMed ID: 29414252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.